NCT03473613View on ClinicalTrials.gov

Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention

PHASE3CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

April 15, 2017

Study Completion Date

April 15, 2017

Conditions
Ovarian Hyperstimulation
Interventions
DRUG

Oral Cabergoline

Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days

DRUG

Calcium Gluconate

Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days

Trial Locations (1)

5131

Ashraf nassif Elmantwe, Cairo

All Listed Sponsors
lead

Benha University

OTHER

NCT03473613 - Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention | Biotech Hunter | Biotech Hunter